ORAL ANTICOAGULANTS IN AMBULATORY AND IN-HOSPITAL TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION ASSOCIATED WITH HYPERTENSION, ISCHEMIC HEART DISEASE AND CHRONIC HEART FAILURE: DATA FROM HOSPITAL REGISTRY RECVASA-CLINIC

Aim. To estimate the rate of oral anticoagulants (OAC) prescription, continuity of anticoagulant therapy in hospital and ambulatory stages along with treatment adherence in patients with atrial fibrillation (AF) associated with hypertension (HT), ischemic heart disease (IHD) and chronic heart failure (CHF) within the registry of cardiovascular diseases. Material and methods. The study included 285 patients with AF combined with HT, IHD and CHF from the hospital registry RECVASA-CLINIC (n=3696). The rate of OAC prescription was evaluated in ambulatory and in-hospital stages according to medical records. Out-patient treatment was estimated via phone contact in 250 participants that represented 96.2% of all survived patients during follow-up of 24.1Ѓ}5.9 months after discharge from hospital. Medical adherence was evaluated using Morisky-Green questionnaire. Results. Mean age of patients was 73.9Ѓ}10.0 years (male – 52.6), CHA2DS2-VASc and HAS-BLED score were estimated as 5.14Ѓ}1.50 и 1.59Ѓ}0.79, respectively. Contraindications to OAC treatment were registered in 34 (11.9%) patients. In pre-hospital stage patients with paroxysmal AF received OAK more rarely comparing to those with permanent and persistent AF (31.8%, 51.7 and 55%, respectively; р<0.05). The rate of OAC administration in pre-hospital stage, on discharge and after 24.1Ѓ}5.9 months follow-up period was 40.4%, 88.1% and 82%, respectively, whereas patients with previous stroke were prescribed OACs more frequently (in 49%, 92.5% and 83.7% of cases, respectively). Only 43% of study participants had good compliance to medical treatment (score of 4) according to Morisky-Green questionnaire. Conclusion. OACs were under prescribed in pre-hospital stage and after 2 years of follow-up in patients with AF combined with HT, IHD and CHF comparing with in-hospital period (40.4% and 82% vs 88.1%). Medical compliance according to Morisky-Green questionnaire was not enough (43%) in high-risk patients after discharge from hospital.

1. Diagnosis and treatment of atrial fibrillation. 2012 RSC/RSSA/RACVS guidelines. Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed by 06.01.2017. (In Russ.) [Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, ВНОА, АССХ (2012). http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 06.01.2017]

2. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78.

3. Haim M., Hoshen M., Reges O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486.

4. Krahn A.D., Manfreda J., Tate R.B., et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–84.

5. Andersson T., Magnuson A., Bryngelsson I.L, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Euro Heart J. 2013;34:1061–7.

6. AHA/ASA Guidelines for the Primary Prevention of Stroke. Stroke. 2014;45:3754-832.

7. Lip G.Y., Nieuwlaat R., Pisters R., et. al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-72.

8. Waldo A.L., Becker R.C., Tapson V.F., Colgan K.J. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46:1729-36.

9. Sulimov V.A., Napalkov D.A., Sokolova A.A. Anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study. Ration Pharmacother Cardiol. 2015;11(1): 116-23. (In Russ.) [Сулимов В.А., Напалков Д.А., Соколова А.А. Антикоагулянтная терапия в реальной клинической практике: данные ретроспективного одномоментного исследования. Рациональная Фармакотерапия в Кардиологии. 2015;11(1):116-23].

10. Loukianov M.M., Boytsov S.A., Yakushin S.S., et.al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases RECVASA). Ration Pharmacother Cardiol. 2014;10(4):366-77. (In Russ.) [Лукьянов М.М., Бойцов С.А., Якушин С.С. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом "фибрилляция предсердий" в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2014;10(4): 366-77].

11. GarcТa-AcuЦa J.M., GonzЗlez-Juanatey J.R., AlegrТa Ezquerra E., et al. Permanent atrial fibrillation in heart disease in Spain. The CARDIOTENS study 1999. Rev Esp Cardiol. 2002;55(9):943-52.

12. RodrТguez-MaЦero M., Bertomeu-GonzЗlez V., Cordero A., et.al. Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years. Rev Port Cardiol. 2013;32(2): 103-9.

13. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.

14. Martsevich S.Y., Navasardyan A.R., Kutishenko N.P., et al. Studying atrial fibrillation on the bais of PROFILE registry. Kardiovaskulyarnaya Terapiya i Profilaktika. 2014;2:35-9. (In Russ.) [Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П. и др. Опыт изучения фибрилляции предсердий на базе регистра ПРОФИЛЬ. Кардиоваскулярная Терапия и Профилактика. 2014;2:35-9].

15. De Caterina R., Renda G., Sangiuolo R., et.al. Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry. G Ital Cardiol (Rome). 2014;2: 99–109.

16. Piccini J.P., Fraulo E.S., Ansell J.E., et.al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011;4:606–12.

17. Linchak R.M., Kompaniets O.G., Nedbaykin A.M., et al. What do doctors think and know about antithrombotic therapy in atrial fibrillation. Kardiologiia. 2014;10:32-8. (In Russ.) [Линчак Р.М., Компаниец О.Г., Недбайкин А.М. и др. Что думают и знают врачи об антитромботической терапии при фибрилляции предсердий? Кардиология. 2014;10:32-8].

18. Hendriks J.M., de Wit R, Crijns H.J.G.M., et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012;33:2692–9.

19. Chugh S.S., Havmoeller R., Narayanan K., et.al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.

20. Moiseev S.V. Anticoagulation therapy adherence: issues and solutions. Klinicheskaya Farmakologiya i Terapiya. 2014;23(4):23-8. (In Russ.) [Моисеев С.В. Приверженность к антикоагулянтной терапии: проблемы и пути решения. Клиническая Фармакология и Терапия. 2014;23(4):23-8].

21. Coleman C.I., Roberts M.S., Sobieraj D.M., et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669–80.

22. Bosworth H.B., Granger B.B., Mendys P., et.al Medication adherence: a call for action. Am Heart Journal. 2011;162(3):412-24.